<p>TransMedics Group, Inc.（纳斯达克代码：TMDX - 获取免费报告）的股票在周一交易中上涨了 6.8%，此前华尔街 Zen 将该股票的评级从持有上调至买入。该股票最高交易价格为 130.70 美元，最后交易价格为 128.76 美元。在交易过程中，约有 501,417 股易手，较平均每日交易量 1,355,177 股下降了 63%。该股票此前收盘价为 120.55 美元。</p>
<ul>
<li>中型股的奇迹：三只在五月份超越销售预期的股票</li>
</ul>
<p>TMDX 已经成为其他多份研究报告的主题。Needham &amp; Company LLC 在 6 月 17 日的报告中重申了对 TransMedics Group 股票的 “持有” 评级。Oppenheimer 在 6 月 17 日的报告中将 TransMedics Group 的股票目标价从 130.00 美元上调至 150.00 美元，并给予该公司 “跑赢大盘” 的评级。摩根士丹利在周五的报告中将 TransMedics Group 的股票目标价从 115.00 美元上调至 123.00 美元，并给予该公司 “同等权重” 的评级。Canaccord Genuity Group 在 7 月 15 日的报告中将 TransMedics Group 的股票目标价从 129.00 美元上调至 142.00 美元，并给予该公司 “买入” 的评级。最后，Piper Sandler 在 6 月 4 日的报告中重申了 “超配” 评级，并将 TransMedics Group 的股票目标价设定为 145.00 美元（之前为 125.00 美元）。三位研究分析师对该股票给予了持有评级，六位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 123.00 美元。</p>
<p>获取 <strong>TransMedics Group</strong> 的提醒：</p>
<p><strong>查看我们关于 TMDX 的最新报告</strong></p>
<h2>内部人士下注</h2>
<ul>
<li>三只在 2025 年表现优异的医疗技术股票</li>
</ul>
<p>在其他 TransMedics Group 的新闻中，董事 David Weill 在 5 月 23 日的交易中出售了 732 股该公司的股票。股票以平均价格 123.88 美元出售，总交易额为 90,680.16 美元。出售后，该董事在公司中持有 12,134 股，价值约为 1,503,159.92 美元。这笔交易代表了其持股比例的 5.69% 下降。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，内部人士 Anil P. Ranganath 在 6 月 9 日的交易中出售了 686 股该公司的股票。股票以平均价格 139.80 美元出售，总交易额为 95,902.80 美元。出售后，该内部人士在公司中持有 13,955 股，价值约为 1,950,909 美元。这笔交易代表了其持股比例的 4.69% 下降。该出售的披露信息可以在这里找到。在过去 90 天内，内部人士已出售 12,418 股公司股票，价值 1,512,613 美元。公司内部人士持有公司股票的 7.00%。</p>
<h2>机构投资者对 TransMedics Group 的看法</h2>
<p>机构投资者和对冲基金最近调整了对该股票的持有。Opal Wealth Advisors LLC 在第二季度购买了 TransMedics Group 的新股份，价值约为 26,000 美元。Sound Income Strategies LLC 在第二季度购买了 TransMedics Group 的新股份，价值约为 48,000 美元。NBC Securities Inc.在第一季度购买了 TransMedics Group 的新股份，价值约为 25,000 美元。Smartleaf Asset Management LLC 在第一季度将其在 TransMedics Group 的持股比例提高了 44.3%。Smartleaf Asset Management LLC 现在持有 440 股该公司的股票，价值 30,000 美元，此前在上个季度又购买了 135 股。最后，Atlas Capital Advisors Inc.在第四季度购买了 TransMedics Group 的新股份，价值约为 31,000 美元。机构投资者持有公司 99.67% 的股票。</p>
<h2>TransMedics Group 股票表现</h2>
<ul>
<li>三只交易者喜爱的高增长股票，投资者应关注</li>
</ul>
<p>该股票的市值为 44.4 亿美元，市盈率为 67.48，贝塔值为 2.09。该公司的债务与股本比率为 1.61，流动比率为 9.86，速动比率为 9.17。该公司的 50 日移动平均价格为 124.51 美元，200 日移动平均价格为 95.50 美元。</p>
<p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）最近在 7 月 30 日宣布了其季度财报。该公司报告每股收益为 0.92 美元，超出市场共识预期的 0.48 美元，超出幅度为 0.44 美元。TransMedics Group 的净利润率为 13.49%，股本回报率为 28.02%。该公司季度收入为 1.5737 亿美元，而分析师预期为 1.4664 亿美元。去年同期，该公司每股收益为 0.35 美元。TransMedics Group 的季度收入同比增长 37.7%。卖方分析师预计 TransMedics Group, Inc.在当前财政年度将发布 1 美元的每股收益。</p>
<h2>关于 TransMedics Group</h2>
<p>（获取免费报告）</p>
<p>TransMedics Group, Inc.是一家商业阶段的医疗技术公司，致力于为美国及国际上的终末期器官衰竭患者转变器官移植治疗。该公司提供器官护理系统（OCS），这是一种便携式器官灌注、优化和监测系统，利用其专有和定制技术在人体外复制接收器官的近生理条件。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 TransMedics Group</li>
<li>这些液化天然气股票是否准备迎来反弹？</li>
<li>三个令人惊讶的盈利赢家改变了他们的市场叙事</li>
<li>如何投资 FAANG 股票</li>
<li>48 小时内的两笔交易如何改变了 Joby Aviation 的一切</li>
<li>深入了解买卖差价</li>
<li>五只塑造明天世界的股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 TransMedics Group 吗？</h2>
<p>在你考虑 TransMedics Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 TransMedics Group 并不在名单上。</p>
<p>虽然 TransMedics Group 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TMDX

<p>TransMedics Group（纳斯达克代码：TMDX）股价上涨 6.8%，因华尔街 Zen 将该股票评级从持有上调至买入。该股最高达到 130.70 美元，最终收于 128.76 美元，交易量下降了 63%。分析师的评级各异，其中三位持有，六位买入，一位强烈买入。公司报告每股收益为 0.92 美元，超出预期，营收为 1.5737 亿美元，同比增长 37.7%。内部人士近期出售了部分股份，机构投资者持有 99.67% 的股份</p>

<p>Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) were up 6.8% during trading on Monday after Wall Street Zen upgraded the stock from a hold rating to a buy rating. The stock traded as high as $130.70 and last traded at $128.76. Approximately 501,417 shares changed hands during trading, a decline of 63% from the average daily volume of 1,355,177 shares. The stock had previously closed at $120.55.</p>
<div class="lb-trans"><p>TransMedics Group, Inc.（纳斯达克代码：TMDX - 获取免费报告）的股票在周一交易中上涨了 6.8%，此前华尔街 Zen 将该股票的评级从持有上调至买入。该股票最高交易价格为 130.70 美元，最后交易价格为 128.76 美元。在交易过程中，约有 501,417 股易手，较平均每日交易量 1,355,177 股下降了 63%。该股票此前收盘价为 120.55 美元。</p>
</div><ul>
<li>Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May</li>
</ul>
<div class="lb-trans"><ul>
<li>中型股的奇迹：三只在五月份超越销售预期的股票</li>
</ul>
</div><p>TMDX has been the topic of a number of other research reports. Needham &amp; Company LLC reaffirmed a &#34;hold&#34; rating on shares of TransMedics Group in a report on Tuesday, June 17th. Oppenheimer raised their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday, June 17th. Morgan Stanley raised their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the company an &#34;equal weight&#34; rating in a report on Friday. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, July 15th. Finally, Piper Sandler reaffirmed an &#34;overweight&#34; rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $123.00.</p>
<div class="lb-trans"><p>TMDX 已经成为其他多份研究报告的主题。Needham &amp; Company LLC 在 6 月 17 日的报告中重申了对 TransMedics Group 股票的 “持有” 评级。Oppenheimer 在 6 月 17 日的报告中将 TransMedics Group 的股票目标价从 130.00 美元上调至 150.00 美元，并给予该公司 “跑赢大盘” 的评级。摩根士丹利在周五的报告中将 TransMedics Group 的股票目标价从 115.00 美元上调至 123.00 美元，并给予该公司 “同等权重” 的评级。Canaccord Genuity Group 在 7 月 15 日的报告中将 TransMedics Group 的股票目标价从 129.00 美元上调至 142.00 美元，并给予该公司 “买入” 的评级。最后，Piper Sandler 在 6 月 4 日的报告中重申了 “超配” 评级，并将 TransMedics Group 的股票目标价设定为 145.00 美元（之前为 125.00 美元）。三位研究分析师对该股票给予了持有评级，六位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 123.00 美元。</p>
</div><p>Get <strong>TransMedics Group</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>TransMedics Group</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Report on TMDX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 TMDX 的最新报告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>三只在 2025 年表现优异的医疗技术股票</li>
</ul>
</div><p>In other TransMedics Group news, Director David Weill sold 732 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the sale, the director owned 12,134 shares in the company, valued at approximately $1,503,159.92. This trade represents a 5.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider owned 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,418 shares of company stock worth $1,512,613. Company insiders own 7.00% of the company's stock.</p>
<div class="lb-trans"><p>在其他 TransMedics Group 的新闻中，董事 David Weill 在 5 月 23 日的交易中出售了 732 股该公司的股票。股票以平均价格 123.88 美元出售，总交易额为 90,680.16 美元。出售后，该董事在公司中持有 12,134 股，价值约为 1,503,159.92 美元。这笔交易代表了其持股比例的 5.69% 下降。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，内部人士 Anil P. Ranganath 在 6 月 9 日的交易中出售了 686 股该公司的股票。股票以平均价格 139.80 美元出售，总交易额为 95,902.80 美元。出售后，该内部人士在公司中持有 13,955 股，价值约为 1,950,909 美元。这笔交易代表了其持股比例的 4.69% 下降。该出售的披露信息可以在这里找到。在过去 90 天内，内部人士已出售 12,418 股公司股票，价值 1,512,613 美元。公司内部人士持有公司股票的 7.00%。</p>
</div><h2>Institutional Investors Weigh In On TransMedics Group</h2>
<div class="lb-trans"><h2>机构投资者对 TransMedics Group 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Opal Wealth Advisors LLC bought a new stake in shares of TransMedics Group during the second quarter valued at approximately $26,000. Sound Income Strategies LLC bought a new stake in shares of TransMedics Group during the second quarter valued at approximately $48,000. NBC Securities Inc. bought a new stake in shares of TransMedics Group during the first quarter valued at approximately $25,000. Smartleaf Asset Management LLC raised its position in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after buying an additional 135 shares during the last quarter. Finally, Atlas Capital Advisors Inc. bought a new stake in shares of TransMedics Group during the fourth quarter valued at approximately $31,000. Institutional investors own 99.67% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近调整了对该股票的持有。Opal Wealth Advisors LLC 在第二季度购买了 TransMedics Group 的新股份，价值约为 26,000 美元。Sound Income Strategies LLC 在第二季度购买了 TransMedics Group 的新股份，价值约为 48,000 美元。NBC Securities Inc.在第一季度购买了 TransMedics Group 的新股份，价值约为 25,000 美元。Smartleaf Asset Management LLC 在第一季度将其在 TransMedics Group 的持股比例提高了 44.3%。Smartleaf Asset Management LLC 现在持有 440 股该公司的股票，价值 30,000 美元，此前在上个季度又购买了 135 股。最后，Atlas Capital Advisors Inc.在第四季度购买了 TransMedics Group 的新股份，价值约为 31,000 美元。机构投资者持有公司 99.67% 的股票。</p>
</div><h2>TransMedics Group Stock Performance</h2>
<div class="lb-trans"><h2>TransMedics Group 股票表现</h2>
</div><ul>
<li>3 High-Growth Stocks Traders Love and Investors Should Watch</li>
</ul>
<div class="lb-trans"><ul>
<li>三只交易者喜爱的高增长股票，投资者应关注</li>
</ul>
</div><p>The stock has a market cap of $4.44 billion, a P/E ratio of 67.48 and a beta of 2.09. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. The firm's 50-day moving average price is $124.51 and its 200-day moving average price is $95.50.</p>
<div class="lb-trans"><p>该股票的市值为 44.4 亿美元，市盈率为 67.48，贝塔值为 2.09。该公司的债务与股本比率为 1.61，流动比率为 9.86，速动比率为 9.17。该公司的 50 日移动平均价格为 124.51 美元，200 日移动平均价格为 95.50 美元。</p>
</div><p>TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million for the quarter, compared to analysts' expectations of $146.64 million. During the same quarter in the previous year, the business posted $0.35 earnings per share. TransMedics Group's quarterly revenue was up 37.7% on a year-over-year basis. Sell-side analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）最近在 7 月 30 日宣布了其季度财报。该公司报告每股收益为 0.92 美元，超出市场共识预期的 0.48 美元，超出幅度为 0.44 美元。TransMedics Group 的净利润率为 13.49%，股本回报率为 28.02%。该公司季度收入为 1.5737 亿美元，而分析师预期为 1.4664 亿美元。去年同期，该公司每股收益为 0.35 美元。TransMedics Group 的季度收入同比增长 37.7%。卖方分析师预计 TransMedics Group, Inc.在当前财政年度将发布 1 美元的每股收益。</p>
</div><h2>About TransMedics Group</h2>
<div class="lb-trans"><h2>关于 TransMedics Group</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.</p>
<div class="lb-trans"><p>TransMedics Group, Inc.是一家商业阶段的医疗技术公司，致力于为美国及国际上的终末期器官衰竭患者转变器官移植治疗。该公司提供器官护理系统（OCS），这是一种便携式器官灌注、优化和监测系统，利用其专有和定制技术在人体外复制接收器官的近生理条件。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than TransMedics Group</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>3 Surprising Earnings Winners Changing Their Market Narrative</li>
<li>How to Invest in the FAANG Stocks</li>
<li>How 2 Deals in 48 Hours Changed Everything for Joby Aviation</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>5 Stocks Shaping Tomorrow’s World</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 TransMedics Group</li>
<li>这些液化天然气股票是否准备迎来反弹？</li>
<li>三个令人惊讶的盈利赢家改变了他们的市场叙事</li>
<li>如何投资 FAANG 股票</li>
<li>48 小时内的两笔交易如何改变了 Joby Aviation 的一切</li>
<li>深入了解买卖差价</li>
<li>五只塑造明天世界的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in TransMedics Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 TransMedics Group 吗？</h2>
</div><p>Before you consider TransMedics Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 TransMedics Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 TransMedics Group 并不在名单上。</p>
</div><p>While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 TransMedics Group 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

TransMedics 集团（NASDAQ:TMDX）股价在分析师上调评级后上涨了 6.8%